PE20060767A1 - Derivados de tetrahidroquinolina como inhibidores de cept - Google Patents
Derivados de tetrahidroquinolina como inhibidores de ceptInfo
- Publication number
- PE20060767A1 PE20060767A1 PE2005001475A PE2005001475A PE20060767A1 PE 20060767 A1 PE20060767 A1 PE 20060767A1 PE 2005001475 A PE2005001475 A PE 2005001475A PE 2005001475 A PE2005001475 A PE 2005001475A PE 20060767 A1 PE20060767 A1 PE 20060767A1
- Authority
- PE
- Peru
- Prior art keywords
- tetrahydroquinoline derivatives
- tetrahydroquinoline
- cept
- inhibitors
- cept inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003530 tetrahydroquinolines Chemical class 0.000 title 1
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 abstract 2
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 abstract 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- -1 ISOPROPYL Chemical class 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004060997A DE102004060997A1 (de) | 2004-12-18 | 2004-12-18 | Chemische Verbindung und ihre Verwendung |
| DE102004061000A DE102004061000A1 (de) | 2004-12-18 | 2004-12-18 | Chemische Verbindung und ihre Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060767A1 true PE20060767A1 (es) | 2006-09-10 |
Family
ID=35841894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001475A PE20060767A1 (es) | 2004-12-18 | 2005-12-16 | Derivados de tetrahidroquinolina como inhibidores de cept |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8124775B2 (enExample) |
| EP (1) | EP1828137B1 (enExample) |
| JP (1) | JP5132317B2 (enExample) |
| KR (1) | KR20070090248A (enExample) |
| AR (1) | AR055011A1 (enExample) |
| AT (1) | ATE555097T1 (enExample) |
| AU (1) | AU2005315770B2 (enExample) |
| BR (1) | BRPI0519602A2 (enExample) |
| CA (1) | CA2591397A1 (enExample) |
| CU (1) | CU23452B7 (enExample) |
| CY (1) | CY1112887T1 (enExample) |
| DK (1) | DK1828137T3 (enExample) |
| DO (1) | DOP2005000259A (enExample) |
| ES (1) | ES2384980T3 (enExample) |
| GT (1) | GT200500377A (enExample) |
| IL (1) | IL184008A (enExample) |
| MA (1) | MA29100B1 (enExample) |
| MX (1) | MX2007007188A (enExample) |
| NO (1) | NO20073146L (enExample) |
| PE (1) | PE20060767A1 (enExample) |
| PL (1) | PL1828137T3 (enExample) |
| PT (1) | PT1828137E (enExample) |
| RU (1) | RU2393151C2 (enExample) |
| SI (1) | SI1828137T1 (enExample) |
| TW (1) | TW200635900A (enExample) |
| UY (1) | UY29276A1 (enExample) |
| WO (1) | WO2006063828A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005324127A1 (en) * | 2004-12-18 | 2006-07-13 | Bayer Healthcare Ag | (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors |
| DE102006012548A1 (de) * | 2006-03-18 | 2007-09-20 | Bayer Healthcare Ag | Substituierte Chromanol-Derivate und ihre Verwendung |
| ATE520696T1 (de) * | 2008-03-05 | 2011-09-15 | Boehringer Ingelheim Int | Tricyclische pyridinderivate, solche verbindungen enthaltende medikamente, ihre verwendung und verfahren zu ihrer herstellung |
| MA34007B1 (fr) | 2010-02-19 | 2013-02-01 | Boehringer Ingelheim Int | Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation |
| US9187450B2 (en) * | 2010-07-09 | 2015-11-17 | Daiichi Sankyo Company, Limited | Substituted pyridine compound |
| WO2012110599A1 (en) | 2011-02-17 | 2012-08-23 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| US9150583B2 (en) | 2011-08-17 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation |
| US9321747B2 (en) | 2012-01-06 | 2016-04-26 | Daiichi Sankyo Company, Limited | Acid addition salt of substituted pyridine compound |
| WO2016016157A1 (en) | 2014-07-30 | 2016-02-04 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4128681A1 (de) * | 1991-08-29 | 1993-03-04 | Bayer Ag | Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| DE19610932A1 (de) | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
| DE19627430A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Bicyclisch kondensierte Pyridine |
| US6207671B1 (en) | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
| HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| DE19704244A1 (de) | 1997-02-05 | 1998-08-06 | Bayer Ag | 5-Hydroxy-alkyl substituierte Phenyle |
| DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
| MA24643A1 (fr) * | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
| DE19741051A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
| DE19741399A1 (de) * | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
| DE19935966A1 (de) | 1999-07-30 | 2001-02-01 | Bayer Ag | Verfahren zur Reduktion von Ketoalkoholen |
| DE10148436A1 (de) | 2001-10-01 | 2003-04-17 | Bayer Ag | Tetrahydrochinoline |
| DE10250687A1 (de) | 2002-10-31 | 2004-05-13 | Bayer Ag | 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung |
| AU2005324127A1 (en) * | 2004-12-18 | 2006-07-13 | Bayer Healthcare Ag | (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors |
-
2005
- 2005-12-15 WO PCT/EP2005/013490 patent/WO2006063828A1/de not_active Ceased
- 2005-12-15 KR KR1020077016219A patent/KR20070090248A/ko not_active Ceased
- 2005-12-15 EP EP05820528A patent/EP1828137B1/de not_active Expired - Lifetime
- 2005-12-15 BR BRPI0519602-7A patent/BRPI0519602A2/pt not_active IP Right Cessation
- 2005-12-15 SI SI200531547T patent/SI1828137T1/sl unknown
- 2005-12-15 CA CA002591397A patent/CA2591397A1/en not_active Abandoned
- 2005-12-15 PL PL05820528T patent/PL1828137T3/pl unknown
- 2005-12-15 US US11/793,482 patent/US8124775B2/en not_active Expired - Fee Related
- 2005-12-15 JP JP2007545948A patent/JP5132317B2/ja not_active Expired - Fee Related
- 2005-12-15 RU RU2007127127/04A patent/RU2393151C2/ru not_active IP Right Cessation
- 2005-12-15 ES ES05820528T patent/ES2384980T3/es not_active Expired - Lifetime
- 2005-12-15 PT PT05820528T patent/PT1828137E/pt unknown
- 2005-12-15 DK DK05820528.7T patent/DK1828137T3/da active
- 2005-12-15 MX MX2007007188A patent/MX2007007188A/es active IP Right Grant
- 2005-12-15 AT AT05820528T patent/ATE555097T1/de active
- 2005-12-15 AU AU2005315770A patent/AU2005315770B2/en not_active Ceased
- 2005-12-16 TW TW094144588A patent/TW200635900A/zh unknown
- 2005-12-16 AR ARP050105313A patent/AR055011A1/es not_active Application Discontinuation
- 2005-12-16 PE PE2005001475A patent/PE20060767A1/es not_active Application Discontinuation
- 2005-12-16 DO DO2005P000259A patent/DOP2005000259A/es unknown
- 2005-12-19 GT GT200500377A patent/GT200500377A/es unknown
- 2005-12-20 UY UY29276A patent/UY29276A1/es not_active Application Discontinuation
-
2007
- 2007-06-18 IL IL184008A patent/IL184008A/en not_active IP Right Cessation
- 2007-06-18 CU CU20070140A patent/CU23452B7/es not_active IP Right Cessation
- 2007-06-18 MA MA30003A patent/MA29100B1/fr unknown
- 2007-06-19 NO NO20073146A patent/NO20073146L/no not_active Application Discontinuation
-
2012
- 2012-02-16 US US13/398,290 patent/US20120142728A1/en not_active Abandoned
- 2012-06-29 CY CY20121100588T patent/CY1112887T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL184008A0 (en) | 2007-10-31 |
| US20080255068A1 (en) | 2008-10-16 |
| GT200500377A (es) | 2006-11-09 |
| MX2007007188A (es) | 2007-08-14 |
| AU2005315770B2 (en) | 2011-12-08 |
| DOP2005000259A (es) | 2006-11-15 |
| KR20070090248A (ko) | 2007-09-05 |
| ATE555097T1 (de) | 2012-05-15 |
| AR055011A1 (es) | 2007-08-01 |
| IL184008A (en) | 2012-03-29 |
| BRPI0519602A2 (pt) | 2009-02-25 |
| JP5132317B2 (ja) | 2013-01-30 |
| CY1112887T1 (el) | 2016-04-13 |
| TW200635900A (en) | 2006-10-16 |
| EP1828137B1 (de) | 2012-04-25 |
| PL1828137T3 (pl) | 2012-09-28 |
| EP1828137A1 (de) | 2007-09-05 |
| AU2005315770A1 (en) | 2006-06-22 |
| MA29100B1 (fr) | 2007-12-03 |
| CU23452B7 (es) | 2009-12-01 |
| NO20073146L (no) | 2007-09-18 |
| UY29276A1 (es) | 2006-07-31 |
| PT1828137E (pt) | 2012-07-04 |
| RU2393151C2 (ru) | 2010-06-27 |
| SI1828137T1 (sl) | 2012-08-31 |
| WO2006063828A1 (de) | 2006-06-22 |
| US8124775B2 (en) | 2012-02-28 |
| US20120142728A1 (en) | 2012-06-07 |
| CA2591397A1 (en) | 2006-06-22 |
| DK1828137T3 (da) | 2012-07-23 |
| RU2007127127A (ru) | 2009-01-27 |
| ES2384980T3 (es) | 2012-07-16 |
| JP2008524145A (ja) | 2008-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111295T1 (el) | Παραγωγα πυριμιδινης χρησιμα για τη θεραπεια ασθενειων που προκαλουνται απο crth2 | |
| BRPI0516905A (pt) | processo para a preparação de um derivado n-[2-(2-piridinil)etil]carboxamida e compostos | |
| PE20060525A1 (es) | Compuestos heterociclicos como inhibidores de cetp | |
| DK2032521T3 (da) | Ny fremgangsmåde til saltfremstilling | |
| TW200736221A (en) | Novel pharmaceutical salts and polymorphs of a Factor Xa inhibitor | |
| CY1109998T1 (el) | Ενδυναμωτες υποδοχεων γλουταμινικου | |
| EA200702541A1 (ru) | Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты | |
| DK2301544T3 (da) | Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer | |
| CY1113494T1 (el) | 8-ΕΤΕΡΟΑΡΥΛΟ-3-ΑΛΚΥΛΟ-1,3-ΔΙΥΔΡΟ-ΙΜΙΔΑΖΟ[4,5-c]ΚΙΝΟΛΙΝ-2-ΟΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ ΡΙ-3 | |
| EA200900779A1 (ru) | Производные дигидропиридина, полезные как ингибиторы протеинкиназы | |
| EA200801341A1 (ru) | КОНДЕНСИРОВАННЫЕ БИЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ mTOR | |
| ATE501721T1 (de) | Chinolin-derivate zur behandlung von latenter tuberkulose | |
| WO2008062478A3 (en) | Improved process for pure montelukast sodium through pure intermediates as well as novel amine salts | |
| WO2006052568A3 (en) | Tgf-beta inhibitors | |
| DK1761520T3 (da) | Kinaseinhibitorer | |
| CY1106132T1 (el) | Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου | |
| CA2665931C (en) | Hydrobenzamide derivatives as inhibitors of hsp90 | |
| EA200802142A1 (ru) | Цинковая соль розувастатина | |
| EA201190293A1 (ru) | Пролекарства триптолида | |
| PE20060767A1 (es) | Derivados de tetrahidroquinolina como inhibidores de cept | |
| DE602005008953D1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
| DE602005025251D1 (de) | Verfahren zur herstellung eines 2-ethylaminopyridinderivats | |
| AR060189A1 (es) | Sales de malato y polimorfos de acido (3s, 5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-dihidro-8-metoxi-4-oxo-3-quinolincarboxilico | |
| EA201170828A1 (ru) | Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза | |
| WO2009001203A3 (en) | An improved process for the preparation of aprepitant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |